AU2014349132A8 - Vaginal inserted estradiol pharmaceutical compositons and methods - Google Patents

Vaginal inserted estradiol pharmaceutical compositons and methods

Info

Publication number
AU2014349132A8
AU2014349132A8 AU2014349132A AU2014349132A AU2014349132A8 AU 2014349132 A8 AU2014349132 A8 AU 2014349132A8 AU 2014349132 A AU2014349132 A AU 2014349132A AU 2014349132 A AU2014349132 A AU 2014349132A AU 2014349132 A8 AU2014349132 A8 AU 2014349132A8
Authority
AU
Australia
Prior art keywords
methods
pharmaceutical compositons
vaginal
estradiol pharmaceutical
vaginal inserted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014349132A
Other versions
AU2014349132A1 (en
Inventor
Julia M. Amadio
Brian A. Bernick
Janice Louise Cacace
Neda IRANI
Peter H. R. Persicaner
Frederick D. SANSCILIO
Thorsteinn Thorsteinsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TherapeuticsMD Inc
Original Assignee
TherapeuticsMD Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/099,562 external-priority patent/US8987237B2/en
Application filed by TherapeuticsMD Inc filed Critical TherapeuticsMD Inc
Priority claimed from PCT/US2014/061811 external-priority patent/WO2015073177A1/en
Publication of AU2014349132A1 publication Critical patent/AU2014349132A1/en
Publication of AU2014349132A8 publication Critical patent/AU2014349132A8/en
Priority to AU2019204658A priority Critical patent/AU2019204658B2/en
Priority to AU2021218231A priority patent/AU2021218231A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Abstract

According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.
AU2014349132A 2013-10-22 2014-10-22 Vaginal inserted estradiol pharmaceutical compositons and methods Abandoned AU2014349132A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2019204658A AU2019204658B2 (en) 2013-10-22 2019-06-28 Vaginal Inserted Estradiol Pharmaceutical Compositions And Methods
AU2021218231A AU2021218231A1 (en) 2013-10-22 2021-08-20 Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361894411P 2013-10-22 2013-10-22
US61/894,411 2013-10-22
US14/099,562 2013-12-05
US14/099,562 US8987237B2 (en) 2011-11-23 2013-12-06 Natural combination hormone replacement formulations and therapies
US201461932140P 2014-01-27 2014-01-27
US61/932,140 2014-01-27
PCT/US2014/061811 WO2015073177A1 (en) 2013-10-10 2014-10-22 Vaginal inserted estradiol pharmaceutical compositons and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019204658A Division AU2019204658B2 (en) 2013-10-22 2019-06-28 Vaginal Inserted Estradiol Pharmaceutical Compositions And Methods

Publications (2)

Publication Number Publication Date
AU2014349132A1 AU2014349132A1 (en) 2016-04-14
AU2014349132A8 true AU2014349132A8 (en) 2016-07-14

Family

ID=55697531

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014349132A Abandoned AU2014349132A1 (en) 2013-10-22 2014-10-22 Vaginal inserted estradiol pharmaceutical compositons and methods
AU2019204658A Active AU2019204658B2 (en) 2013-10-22 2019-06-28 Vaginal Inserted Estradiol Pharmaceutical Compositions And Methods
AU2021218231A Pending AU2021218231A1 (en) 2013-10-22 2021-08-20 Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2019204658A Active AU2019204658B2 (en) 2013-10-22 2019-06-28 Vaginal Inserted Estradiol Pharmaceutical Compositions And Methods
AU2021218231A Pending AU2021218231A1 (en) 2013-10-22 2021-08-20 Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods

Country Status (8)

Country Link
EP (1) EP3060179A4 (en)
JP (1) JP6680672B2 (en)
KR (2) KR102335160B1 (en)
AU (3) AU2014349132A1 (en)
BR (1) BR112016009008B8 (en)
IL (1) IL245139B (en)
MX (1) MX2022002614A (en)
RU (1) RU2713888C2 (en)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739558B1 (en) * 1995-10-05 1997-11-28 Innothera Lab Sa UNITAL GALENIC FORM FOR LOCAL HORMONOTHERAPY OF VAGINAL DROUGHT
FR2759292B1 (en) * 1997-02-10 2000-08-11 Cird Galderma USE OF RETINOIDS AS PIGMENTATION INDUCING AGENTS
WO1999022680A1 (en) * 1997-11-03 1999-05-14 Deschutes Medical Products, Inc. Pessary with medicated cartridge
JP2002510336A (en) * 1998-04-11 2002-04-02 エレカッパ・ユウロテラピッチ・ソシエタ・ペル・アチオニ Pharmaceutical preparations containing water-soluble ketoprofen salts and methods of using the same
WO2003039524A1 (en) * 2001-11-09 2003-05-15 Pharmacia Ab Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
WO2004054576A1 (en) * 2002-12-18 2004-07-01 Ferrer Internacional, S.A. Pharmaceutical compositions of sertaconazole for vaginal use
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
EP1912623A2 (en) * 2005-08-12 2008-04-23 Drugtech Corporation Estrogen compositions and therapeutic methods of use thereof
EP1872775A1 (en) * 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
HUE055562T2 (en) * 2011-11-23 2021-11-29 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
JP6342334B2 (en) * 2012-01-26 2018-06-13 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． Transdermal hormone replacement therapy
WO2013130535A1 (en) * 2012-02-27 2013-09-06 Newgen Biopharma Corporation Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same

Also Published As

Publication number Publication date
RU2713888C2 (en) 2020-02-10
AU2019204658A1 (en) 2019-07-18
MX2022002614A (en) 2022-04-11
AU2014349132A1 (en) 2016-04-14
IL245139B (en) 2020-08-31
IL245139A0 (en) 2016-06-30
KR20160062097A (en) 2016-06-01
BR112016009008A2 (en) 2017-08-01
KR102335160B1 (en) 2021-12-03
KR20210148435A (en) 2021-12-07
JP2016534025A (en) 2016-11-04
AU2019204658B2 (en) 2021-05-20
AU2021218231A1 (en) 2021-09-09
BR112016009008B1 (en) 2022-09-06
EP3060179A4 (en) 2017-05-17
RU2016118396A3 (en) 2018-07-17
RU2016118396A (en) 2017-11-28
KR102488424B1 (en) 2023-01-12
BR112016009008B8 (en) 2023-01-31
JP6680672B2 (en) 2020-04-15
EP3060179A1 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
MX2014015899A (en) Soluble estradiol capsule for vaginal insertion.
MX2018002301A (en) Glycan compositions and uses thereof.
PH12016500024A1 (en) Bromodomain inhibitor
PH12015502261A1 (en) Macrocyclic deaza-purinones for the treatment of viral infections
TN2013000310A1 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
NZ712350A (en) Abiraterone acetate formulation
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
MX2016008448A (en) Var2csa-drug conjugates.
WO2012112410A3 (en) Micronized placental tissue compositions and methods for making and using the same
UA109464C2 (en) Spiro-oxindoles as mdm2 antagonists
MX2015009106A (en) Solid solution compositions and use in severe pain.
MX2015012833A (en) Ceftolozane antibiotic compositions.
IN2013MU03583A (en)
EP3686184A3 (en) Ionizable compounds and compositions and uses thereof
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
UA115357C2 (en) Pyridin-4-yl derivatives
MX2016005092A (en) Vaginal inserted estradiol pharmaceutical compositons and methods.
TR201910866T4 (en) Combined preparations for cancer treatment.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
AU2016356504A8 (en) 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
MX2015008486A (en) Compositions and methods for treating bacterial infections.
MX2015016603A (en) Corticosteroid compositions.
EA201492238A1 (en) COMPOSITION MIZOPROSTOL
EP4233915A3 (en) Modified release formulations of viloxazine
MX2022002614A (en) Vaginal inserted estradiol pharmaceutical compositons and methods.

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 30 , NO 15 , PAGE(S) 2041 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME THERAPEUTICSMD, INC., APPLICATION NO. 2014349132, UNDER INID (31) INSERT 14/099,562; UNDER INID (32) INSERT THE DATE 06.12.13

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted